Xencor Inc (NASDAQ: XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs. The company leverages its protein engineering expertise to design XmAb drug candidates with improved properties such as bispecific structure and extended half-life. These candidates are advanced into clinical development to evaluate their potential for later stage development, partnership, or commercialization.

Xencor generates revenue primarily through licensing and collaboration agreements with pharmaceutical and biotechnology partners, which include upfront payments, milestone payments, and royalties on net sales of approved products. The company also earns royalties from three marketed medicines that were developed using its XmAb technology, such as Monjuvi and Ultomiris. Additionally, Xencor may receive research funding and other consideration from its collaborative arrangements.

Xencor occupies a niche position in the biopharmaceutical industry as a pioneer of Fc domain engineering, with a proprietary platform that enables the creation of multispecific antibodies and other engineered formats. Its competitors include large pharmaceutical companies and biotechnology firms such as Amgen, Genmab, Regeneron, Roche, Janssen, and Astellas, which are also developing bispecific antibody therapies. Xencor's competitive advantage lies in its modular XmAb technology, extensive patent estate covering thousands of Fc variants, and its ability to partner while retaining key rights to its leading programs.

Xencor's customer base consists of the pharmaceutical and biotechnology companies that license its technology or collaborate on drug development, as well as the patients who ultimately receive the partnered medicines. Specific collaborators and customers include Incyte, which markets Monjuvi; Zenas and its partner Bristol Myers Squibb, which develop obexelimab; Amgen, which advances xaluritamig; Astellas, which develops ASP2138; Janssen, which works on JNJ-9401 and JNJ-1493; Alexion, which commercializes Ultomiris; Vir Bio, Novo Nordisk, Gilead, and Novartis, which license various XmAb Fc domains for their own programs.